Prime Medicine is a Cambridge, Massachusetts biotechnology company developing gene editing medicines for genetic diseases. It last closed at $3.55 on Nov 20, down 7.55% on the day. The next earnings report for PRME is expected around Tue, Mar 2, 2027. For the quarter ended Sep 2026, PRME reported EPS of -$0.22 on revenue of $4.2M, with revenue up 243.9% from a year ago. Over its last 8 reports the stock moved an average of 7.1% the session after earnings.
AI Auto Pilots
Is PRME in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PRME.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on PRMEStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
PRME · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend
The stock is 21% below its 20 day and 5% below its 50 day average. It is 1% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the 200 day average at $3.51, and the nearest resistance the swing high (May 29) at $3.56.
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 13.3%/day
Key levels
$5.9152 week high+66.5%
$4.3120 day average+21.4%
$3.83Pivot R1+7.9%
$3.7450 day average+5.4%
$3.66Pivot+3.1%
$3.56Swing high (May 29)+0.3%
$3.55100 day average+0.0%
$3.55Last close
$3.51200 day average−1.1%
$3.38Pivot S1−4.8%
$3.38Swing low (Oct 23)−4.8%
$2.6752 week low−24.8%
Indicators
RSI (14)
43.28
Middle of its range
Neutral
MACD
-0.02
Below its signal line
Bearish
Stochastic
6.8
Near the bottom of its range
Oversold
ADX (14)
19.7
No clear trend
Williams %R
-96.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-114.1
Oversold below −100, overbought above 100
Oversold
Rate of change
−23.7%
Change over 10 sessions
Bearish
ATR (14)
$0.47
Typical daily range, 13.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
Bounce inside a longer downtrend
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 22.4%/day
Key levels
$5.9152 week high+66.5%
$4.3120 day average+21.4%
$3.83Pivot R1+7.9%
$3.7450 day average+5.4%
$3.66Pivot+3.1%
$3.56Swing high (May 29)+0.3%
$3.55100 day average+0.0%
$3.55Last close
$3.51200 day average−1.1%
$3.38Pivot S1−4.8%
$3.38Swing low (Oct 23)−4.8%
$2.6752 week low−24.8%
Indicators
RSI (14)
49.36
Middle of its range
Neutral
MACD
0.18
Above its signal line
Bullish
Stochastic
44.4
Middle of its range
Neutral
ADX (14)
23.9
Weak trend
Williams %R
-75.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
42.6
Oversold below −100, overbought above 100
Neutral
Rate of change
+13.4%
Change over 10 sessions
Bullish
ATR (14)
$0.80
Typical daily range, 22.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for PRME
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PRME did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow PRME usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for PRMEHow many large options trades hit PRME, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in PRME in the last 90 days.
From SEC Form 4 filings by PRME's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PRME is in one of them and how their past PRME trades turned out.
Prime Medicine is a biotechnology company based in Cambridge, Massachusetts. It develops gene editing medicines built on a technology called Prime Editing, which is designed to rewrite specific sections of DNA without cutting both strands of the double helix. The company's programs target inherited diseases, with early focus on conditions affecting the liver and lungs and on certain blood disorders. Its medicines are intended for patients with these genetic conditions and the doctors who treat them.